Last checked at 25 Oct 2013 07:00
AIM:SAR 25 October 2013
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum to Present at London Investor Show and at BIO Europe
Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that CEO Dr Tim Mitchell will present an update of Sareum's progress at the London Investor Show, which takes place at Olympia, London, today.
Dr Mitchell will also make a more detailed presentation on Sareum's research programmes at BIO-Europe, which is being held in Vienna, Austria, on Tuesday 5 November. BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry.
Sareum's CEO, Dr Tim Mitchell, commented: "These exciting events offer us ideal opportunities to present our latest developments to both investors and our industry peers."
Sareum Holdings plc |
|
Tim Mitchell | 01223 497 700 |
Sanlam Securities UK Limited (Nomad) | |
Simon Clements | 020 7628 2200 |
Hybridan LLP (Broker) |
|
Claire Noyce, William Lynne | 020 7947 4350 / 020 7947 4361 |
Media enquiries: |
|
The Communications Portfolio Ltd |
|
Ariane Comstive Ariane.comstive@communications-portfolio.co.uk | 020 7536 2026 |
Notes for editors:
About Sareum Holdings plc
Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licencing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.
Sareum is working with the Cancer Research Technology Pioneer Fund (CPF) and BACIT Ltd to progress its Checkpoint Kinase 1 (Chk1) cancer research programme through pre-clinical development and Phase 1 clinical trials. The pre-clinical development candidate has been shown to increase the effectiveness of current cancer therapeutics in in vivo cancer models.
SKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery technology platform that has so far produced the Company's Aurora+FLT3, Aurora+ALK, VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR. For further information, please visit www.sareum.co.uk